IMU-838

Drug

Related News

Immunic Presents New Phase 2 CALLIPER Data, Secures $400M for Vidofludimus Calcium

May 28, 2026

Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.

Immunic reports Q1 2026 results after $200 million upfront private placement

May 13, 2026

Immunic reported first-quarter 2026 results and said a $200 million upfront private placement is expected to fund phase 3 ENSURE trials in relapsing MS. The financing could provide up to $400 million in gross proceeds.